Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Study of Oral LOXO-338 in Patients With Advanced Blood Cancers
NCT05024045 · View on ClinicalTrials.gov ↗
Study Summary
The purpose of this study is to find out whether the study drug, LOXO-338, is safe and effective in patients with advanced blood cancer. Patients must have already received standard therapy. The study may last up to approximately 3 years.
Conditions Studied
Interventions
- DRUG Pirtobrutinib
- DRUG LOXO-338
Study Locations (20)
Other
- CHRU de Montpellier-Hopital St Eloi — Montpellier
- Centre Hospitalier Universitaire de Nantes - L' Hopital l'hôtel-Dieu — Nantes
- Institut Curie — Paris
- Centre hospitalier universitaire de Haut Leveque — Pessac
- IRCCS - AOU di Bologna — Bologna
California
- City of Hope National Medical Center — Duarte
- University of California San Francisco, Medical Center at Paranassus — San Francisco
Florida
- Mayo Clinic in Florida — Jacksonville
- Sylvester Comprehensive Cancer Center — Miami
Arizona
- The University of Arizona Cancer Center — Tucson
Georgia
- Emory University — Atlanta
Indiana
- Indiana Blood & Marrow Transplantation (IBMT) — Indianapolis
Kansas
- University of Kansas Medical Center — Westwood
Massachusetts
- Tufts Medical Center — Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 316 participants |
| Start Date | 2021-09-30 |
| Est. Completion | 2026-06 |
| Phase | Phase 1 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05024045
The ClinicalTrials.gov registry entry for NCT05024045 describes a study currently listed as active not recruiting. It is categorized as Phase 1, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 316 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 704 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 7 conditions, with Multiple Myeloma appearing as the primary indexed condition, and to 2 interventions — of which Pirtobrutinib is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT05024045 reports 20 study locations spanning 14 distinct geographic areas — top geographies include Other, California, Florida. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT05024045 about?
NCT05024045 is a clinical study titled "Study of Oral LOXO-338 in Patients With Advanced Blood Cancers". The purpose of this study is to find out whether the study drug, LOXO-338, is safe and effective in patients with advanced blood cancer. Patients must have already received standard therapy. The study may last up to approximately 3 years.
What is the current status of trial NCT05024045?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 316 participants. The study started on 2021-09-30. Estimated completion is 2026-06.
What conditions does trial NCT05024045 study?
This clinical trial studies the following conditions: Multiple Myeloma, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, B-cell Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT05024045?
The interventions under investigation include: Pirtobrutinib (DRUG), LOXO-338 (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT05024045?
This trial is sponsored by Eli Lilly and Company, which has 704 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT05024045 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Georgia, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.